FDA Approves Xbrane Biopharma’s Lucamzi Biosimilar

Glance reports that the FDA has approved Xbrane Biopharma’s Lucamzi, a Lucentis biosimilar with the nonproprietary name ranibizumab-blrz. The regulatory decision adds an FDA-approved biosimilar to the intravitreal injection category.

According to Glance, Lucamzi is expected to launch in 2027. The report identifies the product as the latest intravitreal injection with the same five retinal indications as its reference biologic.

FDA approval for Lucamzi

The approval concerns Lucamzi, Xbrane Biopharma’s ranibizumab-blrz biosimilar. Glance characterizes Lucamzi as a Lucentis biosimilar and reports that it shares its reference biologic’s five retinal indications.

For pharmaceutical and biotech professionals working in ophthalmology, the FDA action is a defined regulatory milestone. The available report identifies the product, company, biosimilar designation, route of administration, indication count, and expected launch year.

Glance describes Lucamzi as an intravitreal injection. The report does not provide additional launch details beyond its expected 2027 timing.

Expected 2027 launch

Glance reports that Lucamzi is expected to launch in 2027. That timing follows the FDA approval reported for Xbrane Biopharma’s biosimilar.

The product’s reported alignment with the reference biologic’s five retinal indications is central to the announcement. Lucamzi is identified by Glance as ranibizumab-blrz, an intravitreal injection, and a Lucentis biosimilar.

Commercial teams following retinal care can use the report as an update on the product’s regulatory status and stated timing. The evidence supplied by Glance supports the FDA approval, the expected 2027 launch, the intravitreal injection format, and the same five retinal indications as the reference biologic.

Reported details

• Company: Xbrane Biopharma
• Product: Lucamzi
• Nonproprietary name: ranibizumab-blrz
• Regulatory event: FDA approval
• Product type: Lucentis biosimilar
• Administration: Intravitreal injection
• Indications: Same five retinal indications as the reference biologic
• Expected launch: 2027